Your browser doesn't support javascript.
Intelligent classification of platelet aggregates by agonist type.
Zhou, Yuqi; Yasumoto, Atsushi; Lei, Cheng; Huang, Chun-Jung; Kobayashi, Hirofumi; Wu, Yunzhao; Yan, Sheng; Sun, Chia-Wei; Yatomi, Yutaka; Goda, Keisuke.
  • Zhou Y; Department of Chemistry, University of Tokyo, Tokyo, Japan.
  • Yasumoto A; Department of Clinical Laboratory Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
  • Lei C; Department of Chemistry, University of Tokyo, Tokyo, Japan.
  • Huang CJ; Institute of Technological Sciences, Wuhan University, Hubei, China.
  • Kobayashi H; Department of Photonics, National Chiao Tung University, Hsinchu, Taiwan.
  • Wu Y; Department of Chemistry, University of Tokyo, Tokyo, Japan.
  • Yan S; Department of Chemistry, University of Tokyo, Tokyo, Japan.
  • Sun CW; Department of Chemistry, University of Tokyo, Tokyo, Japan.
  • Yatomi Y; Department of Photonics, National Chiao Tung University, Hsinchu, Taiwan.
  • Goda K; Department of Clinical Laboratory Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Elife ; 92020 05 12.
Article in English | MEDLINE | ID: covidwho-245716
ABSTRACT
Platelets are anucleate cells in blood whose principal function is to stop bleeding by forming aggregates for hemostatic reactions. In addition to their participation in physiological hemostasis, platelet aggregates are also involved in pathological thrombosis and play an important role in inflammation, atherosclerosis, and cancer metastasis. The aggregation of platelets is elicited by various agonists, but these platelet aggregates have long been considered indistinguishable and impossible to classify. Here we present an intelligent method for classifying them by agonist type. It is based on a convolutional neural network trained by high-throughput imaging flow cytometry of blood cells to identify and differentiate subtle yet appreciable morphological features of platelet aggregates activated by different types of agonists. The method is a powerful tool for studying the underlying mechanism of platelet aggregation and is expected to open a window on an entirely new class of clinical diagnostics, pharmacometrics, and therapeutics.
Platelets are small cells in the blood that primarily help stop bleeding after an injury by sticking together with other blood cells to form a clot that seals the broken blood vessel. Blood clots, however, can sometimes cause harm. For example, if a clot blocks the blood flow to the heart or the brain, it can result in a heart attack or stroke, respectively. Blood clots have also been linked to harmful inflammation and the spread of cancer, and there are now preliminary reports of remarkably high rates of clotting in COVID-19 patients in intensive care units. A variety of chemicals can cause platelets to stick together. It has long been assumed that it would be impossible to tell apart the clots formed by different chemicals (which are also known as agonists). This is largely because these aggregates all look very similar under a microscope, making it incredibly time consuming for someone to look at enough microscopy images to reliably identify the subtle differences between them. However, finding a way to distinguish the different types of platelet aggregates could lead to better ways to diagnose or treat blood vessel-clogging diseases. To make this possible, Zhou, Yasumoto et al. have developed a method called the "intelligent platelet aggregate classifier" or iPAC for short. First, numerous clot-causing chemicals were added to separate samples of platelets taken from healthy human blood. The method then involved using high-throughput techniques to take thousands of images of these samples. Then, a sophisticated computer algorithm called a deep learning model analyzed the resulting image dataset and "learned" to distinguish the chemical causes of the platelet aggregates based on subtle differences in their shapes. Finally, Zhou, Yasumoto et al. verified iPAC method's accuracy using a new set of human platelet samples. The iPAC method may help scientists studying the steps that lead to clot formation. It may also help clinicians distinguish which clot-causing chemical led to a patient's heart attack or stroke. This could help them choose whether aspirin or another anti-platelet drug would be the best treatment. But first more studies are needed to confirm whether this method is a useful tool for drug selection or diagnosis.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Platelet Aggregation / Neural Networks, Computer Type of study: Prognostic study Limits: Humans Language: English Year: 2020 Document Type: Article Affiliation country: ELife.52938

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Platelet Aggregation / Neural Networks, Computer Type of study: Prognostic study Limits: Humans Language: English Year: 2020 Document Type: Article Affiliation country: ELife.52938